Trailing-twelve-month (TTM) revenue is $70.96 Million with a year-over-year growth of (17.24%). Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $1,936,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-05 |
| Q4 FY2025Period ended 2025-12-31 | $17,755,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-26 |
| Q1 FY2026Period ended 2026-03-31 | $19,355,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-05 |
| Q2 FY2026Period ended 2026-06-30 | $31,914,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-06 |
| TTM revenue | $70,960,000 |
Current P/S: $7,700,237,566 market capitalization ÷ $70,960,000 TTM revenue = 108.52x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T15:55:03.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $31.91M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T15:56:03.222Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Collaboration Revenues | N/A | N/A | N/A | N/A | $3M | $9M |
| License | N/A | N/A |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20252025-12-31 · USD |
|---|---|
| CHINA | $600,000 |
$70.96M
$70.96 Million
(17.24%)
vs. $85.74M a year ago (TTM)
+4.19%
5 Year compound annual growth rate
1 Year
(17.24%)
3 Year
+92.44%
5 Year
+4.19%
10 Year
+8.32%
15 Year
+22.67%
20 Year
+12.39%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $88.04M | +$69.56M | +376.56% |
| 2024 | $18.47M | +$10.94M | +145.34% |
| 2023 | $7.53M | ($87.06M) | (92.04%) |
| 2022 | $94.59M | +$24.16M | +34.30% |
| 2021 | $70.43M | +$14.60M | +26.15% |
| 2020 |
TTM Growth
(17.24%)
3-Year CAGR
+92.44%
5-Year CAGR
+4.19%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T15:56:03.222Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
| $0 |
| N/A |
| N/A |
| Milestone | N/A | N/A | $1M | $4M | N/A | N/A |
|---|
| Milestone Fees | $0 | N/A | N/A | N/A | N/A | N/A |
|---|
| Reimbursements | $7M | N/A | N/A | N/A | N/A | N/A |
|---|
| Research And Development | N/A | $11M | $7M | $4M | N/A | N/A |
|---|
| Research And Development Milestone Grant And Other Revenues Net | $10M | $7M | N/A | N/A | N/A | N/A |
|---|
| $55.83M |
| +$28.96M |
| +107.79% |
| 2019 | $26.87M | ($4.63M) | (14.71%) |
| 2018 | $31.50M | +$18.13M | +135.64% |
| 2017 | $13.37M | ($93.04M) | (87.44%) |
| 2016 | $106.41M | +$77.75M | +271.30% |
